Theravance Biopharma to Host Key Opinion Leader Event Focused on the Unmet Medical Need in the Treatment of Neurogenic Orthostatic Hypotension
Dr. Freeman is Professor of Neurology at the
This event is intended for institutional investors, sell-side analysts, and investment bankers. Please RSVP in advance if you plan to attend, as space is limited.
A live webcast and replay of the event will be accessible here or by visiting the Investor Relations section of
In our relentless pursuit of this objective, we strive to apply insight and innovation at each stage of our business, including research, development and commercialization, and utilize both internal capabilities and those of partners around the world. Our research efforts are focused in the areas of inflammation and immunology. Our research goal is to design localized medicines that target diseased tissues, without systemic exposure, in order to maximize patient benefit and minimize risk. These efforts leverage years of experience in developing localized medicines for the lungs to treat respiratory disease. The first potential medicine to emerge from our research focus on immunology and localized treatments is an oral, intestinally restricted pan-Janus kinase (JAK) inhibitor, currently in development to treat a range of inflammatory intestinal diseases. Our pipeline of internally discovered product candidates will continue to evolve with the goal of creating transformational medicines to address the significant needs of patients.
In addition, we have an economic interest in future payments that may be made by
For more information, please visit www.theravance.com.
THERAVANCE®, the Cross/Star logo, and VIBATIV® are registered trademarks of the
Head of Investor Relations
View original content with multimedia:http://www.prnewswire.com/news-releases/theravance-biopharma-to-host-key-opinion-leader-event-focused-on-the-unmet-medical-need-in-the-treatment-of-neurogenic-orthostatic-hypotension-300649979.html